Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas

Table 1

Clinicopathological characteristics of the study subjects.

lp	Histological type	Age	Menopausal status	Bilateral	Size; Left/right (cm)	Stage	Mutation NRAS
1	Cystadenoma papillare serosum proliferans	48	Premenopausal	+	13/10	IC	No
2	Cystadenoma papillare superficiale proliferans	27	Premenopausal	−	18	IA	No
3	Cystadenoma papillare serosum proliferans	47	Premenopausal	−	9	IA	No
4	Cystadenoma papillare serosum proliferans	43	Premenopausal	+	7/6	IB	No
5	Cystadenoma papillare serosum proliferans	35	Premenopausal	−	5	IA	No
6	Cystadenoma papillare serosum proliferans	72	Postmenopausal	−	9	IA	No
7	Cystadenoma papillare serosum proliferans	60	Postmenopausal	+	4/5	IB	No
8	Cystadenocarcinoma papillare serosum	59	Postmenopausal	−	8	IA	No
9	Cystadenocarcinoma serosum	50	Premenopausal	+	6/9	IB	Yes
10	Cystadenocarcinoma serosum	66	Postmenopausal	−	23	IA	No
11	Cystadenocarcinoma papillare serosum	80	Postmenopausal	−	12	IA	No
12	Cystadenocarcinoma serosum	43	Premenopausal	−	7	IC	No